89 results
8-K
EX-99.1
VERV
Verve Therapeutics Inc
8 May 24
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
7:15am
, independent risk factor for ASCVD, ischemic stroke, and aortic stenosis.
Under the terms of the collaboration established in June 2023, Verve
DEFA14A
VERV
Verve Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
7:56am
of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. 3.Approval, on an advisory basis
8-K
VERV
Verve Therapeutics Inc
2 Apr 24
Other Events
7:13am
, in consultation with the study’s independent data and safety monitoring board, has decided to pause enrollment in the Heart-1 trial. Verve is conducting
S-8
le47f
27 Feb 24
Registration of securities for employees
8:32am
S-8
EX-23.2
zq54z6v4pkcjuwvsj3js
27 Feb 24
Registration of securities for employees
8:32am
S-8
EX-99.3
evgvqk6hm qaxxbww3
27 Feb 24
Registration of securities for employees
8:32am
8-K
EX-99.1
t5espeyf 4sriwphp
27 Feb 24
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
7:45am
8-K
EX-1.1
665d tqzx
29 Nov 23
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
4:54pm
424B5
7td1iih bjsln
29 Nov 23
Prospectus supplement for primary offering
4:47pm
424B5
sesbi4tna069fdika5
28 Nov 23
Prospectus supplement for primary offering
4:25pm
8-K
wv23bh2ndm7
13 Nov 23
Other Events
6:34am